Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.
Dr. Temple Grandin was the featured guest of the latest ISB-Town Hall Seattle Science Series. Grandin discussed her new book – “The Outdoor Scientist: The Wonder of Observing the Natural World” – and a variety of other topics. Following her talk, she joined ISB President Dr. Jim Heath for a wide ranging Q&A discussion.
Daniel Chen, an undergraduate researcher in ISB’s Heath Lab and junior at the University of Washington, has been awarded a prestigious Goldwater Scholarship. Chen has been a key member of ISB’s COVID-19 Immune Response Study.
Providence President and CEO Dr. Rod Hochman joined ISB President and Professor Dr. Jim Heath for an hour-long conversation hosted by ISB and Town Hall Seattle about how healthcare and science will be different in a post-pandemic world.
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.
Dr. Knatokie Ford was the featured speaker of a virtual event hosted by ISB and Town Hall Seattle, and shared many of the experiences that helped pave her way to become a leading voice in STEM policy and advocacy, and identified several ways parents and teachers can encourage kids to become tomorrow’s STEM professionals.
In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.
ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.
We created a new brand identity — including logo and tag line — to reflect ISB’s evolution since our inception in 2000, and ahead of our 20th anniversary. ISB is proud to be a part of the vibrant research community in Seattle, and is committed to translational and collaborative science.
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.